3,429 Shares in Amgen Inc. $AMGN Acquired by M Holdings Securities Inc.

Key Points

• M Holdings Securities acquired a new 3,429-share position in Amgen during the third quarter, valued at approximately $1.584 million; institutional investors collectively own 76.5% of the stock.
• Amgen reported quarterly earnings of $6.45 per share, beating the $5.79 consensus estimate, while revenue of $10.37 billion also exceeded forecasts and rose 8.5% year over year.
• The company declared a quarterly dividend of $2.52 per share, equivalent to $10.08 annually and a 2.2% yield.

M Holdings Securities Inc. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 3,429 shares of the medical research company's stock, valued at approximately $1,584,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Wellington Altus USA Inc. raised its holdings in Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company's stock worth $28,000 after purchasing an additional 34 shares during the period. Quest 10 Wealth Builders Inc. grew its holdings in Amgen by 220.0% during the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company's stock valued at $34,000 after purchasing an additional 55 shares during the period. Nvwm LLC grew its holdings in Amgen by 412.5% during the third quarter. Nvwm LLC now owns 82 shares of the medical research company's stock valued at $35,000 after purchasing an additional 66 shares during the period. Security National Bank of Sioux City Iowa IA bought a new stake in Amgen during the second quarter valued at about $36,000. Finally, PFS Partners LLC grew its holdings in Amgen by 95.5% during the third quarter. PFS Partners LLC now owns 86 shares of the medical research company's stock valued at $36,000 after purchasing an additional 42 shares during the period. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Price Performance

NASDAQ:AMGN opened at $465.23 on Tuesday. The business's 50-day simple moving average is $423.08 and its two-hundred day simple moving average is $378.80. Amgen Inc. has a 52 week low of $312.39 and a 52 week high of $483.99. The stock has a market cap of $251.52 billion, a PE ratio of 26.99, a P/E/G ratio of 3.47 and a beta of 0.43. The company has a quick ratio of 1.13, a current ratio of 1.48 and a debt-to-equity ratio of 3.60.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping analysts' consensus estimates of $5.79 by $0.66. The firm had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The business's quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.64 earnings per share. As a group, analysts forecast that Amgen Inc. will post 23.33 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen's dividend payout ratio is presently 58.47%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New AHA 2026 data reinforced Repatha’s potential: an analysis found it cost-effective for high-risk patients without a prior heart attack or stroke, while a separate long-term analysis associated treatment with a 29% lower risk of major cardiovascular events in patients with ASCVD. The findings could support wider use, though the reported analyses do not guarantee future sales growth. Article: New Repatha data at AHA 2026
• Positive Sentiment: Amgen is heading into ACR week with a dazodalibep update expected November 11, creating a near-term clinical catalyst for its pipeline. The article headline does not specify the results, so the update’s impact will depend on the data. Article: Amgen stock heads into ACR week with dazodalibep update
• Positive Sentiment: An article highlighted experimental obesity drug MariTide’s potential to reduce dosing from 52 injections a year to four. If borne out in clinical development, less frequent dosing could be a competitive advantage; the drug remains experimental. Article: Amgen's new drug could mean fewer shots for obesity patients
• Neutral Sentiment: Amgen shares rose in Monday trading but underperformed the broader market, indicating the move was not as strong as the overall market’s. Article: Amgen stock rises Monday, still underperforms market
• Negative Sentiment: ETFs were net sellers of $68.5 million of AMGN on November 5, a potential near-term supply headwind, although 51 funds bought shares and 20 sold. Article: ETFs are net sellers of Amgen

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company's stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.85% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently commented on AMGN. Wells Fargo & Company raised their price objective on Amgen from $430.00 to $460.00 and gave the stock an "equal weight" rating in a research note on Wednesday, November 4th. HSBC cut Amgen from a "buy" rating to a "hold" rating and lowered their price objective for the company from $445.00 to $425.00 in a research report on Thursday, September 10th. Bank of America boosted their price objective on Amgen from $312.00 to $317.00 and gave the company an "underperform" rating in a research note on Wednesday, August 5th. Freedom Broker lowered shares of Amgen from a "buy" rating to a "hold" rating and increased their target price for the stock from $450.00 to $470.00 in a report on Friday. Finally, Royal Bank Of Canada raised their target price on shares of Amgen from $430.00 to $470.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, Amgen presently has a consensus rating of "Hold" and a consensus target price of $422.76.

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company's medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.